Patient Support Line 1-866-433-8000, Monday - Friday: 8:00 AM to 8:00 PM ET
In people who have HR+, HER2- stage 2 or stage 3 early breast cancer (eBC) with a high risk of coming back, KISQALI is proven to significantly reduce the risk of cancer returning*
Ask your doctor about KISQALI
eBC clinical trial results
In a study of more than 5000 people who have HR+, HER2- eBC with a high risk of returning, 2549 people were scheduled to receive KISQALI for 3 years. Along with KISQALI, they also received hormone therapy for 5 or more years. The study was designed to see if adding KISQALI to hormone therapy could lower the risk of breast cancer returning compared with taking hormone therapy alone. At 3 years, 91% of people taking KISQALI + hormone therapy were cancer free compared with 88% of people taking hormone therapy alone.
KISQALI + hormone therapy cut the risk of cancer returning by 25% vs hormone therapy alone.
*For people who have HR+, HER2- eBC with a high risk of returning, people who had stage 2 or stage 3 eBC, and people with and without cancer in their lymph nodes.